NCT05791071

Brief Summary

A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Feb 2023

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2023

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

February 27, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 30, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 29, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 29, 2023

Completed
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

4 months

First QC Date

February 27, 2023

Last Update Submit

February 24, 2025

Conditions

Keywords

ASDVirtual RealityVRSocial CommunicationApplied Behavior Analysis Therapy

Outcome Measures

Primary Outcomes (1)

  • Autism Impact Measure (AIM) Assessment

    The AIM is a 25-item parent questionnaire targeting sensitivity to change of core ASD symptoms. The questionnaire uses a 2-week recall period with items rated on two corresponding 5-point scales (frequency and impact). The items cover distinct sub-domains of ASD symptoms including Repetitive Behavior, Atypical Behavior, Social Reciprocity, and Peer Interaction. A composite score is also calculated.

    The AIM takes approximately 30 minutes to complete.

Secondary Outcomes (1)

  • CARS-2

    The CARS-3 takes approximately 5-10 minutes to complete after the information needed to make the ratings is collected

Other Outcomes (3)

  • AIM sub-domain scores

    The AIM takes approximately 30 minutes to complete.

  • Vineland-3 Adaptive Behavior Composite and sub-domain scores

    The Vineland-3 Comprehensive Interview Form takes approximately 60-90 minutes to complete

  • Adverse events related to VR use

    5-10 minutes as needed to fill out AE form

Study Arms (2)

Floreo VR Building Social Connections

EXPERIMENTAL

Participants will receive Floreo VR Building Social Connections lessons approximately 3 times a week for no more than 15 minutes per session.

Device: Floreo VR Building Social Connections

Sham

SHAM COMPARATOR

Participants will receive non-interventional active VR videos approximately 3 times a week for no more than 15 minutes per session.

Device: Sham

Interventions

Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.

Floreo VR Building Social Connections
ShamDEVICE

This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.

Sham

Eligibility Criteria

Age4 Years - 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Males and females aged 4 years to 10 years 11 months of age (up to 11th birthday at randomization).
  • Patients or legally authorized representatives must provide written informed consent and be willing and able to comply with study procedures. Participants must provide informed assent as clinically appropriate.
  • A diagnosis of autism spectrum disorder on the basis of the clinical judgement of a qualified clinician according to DSM-5 criteria, supported by either the Autism Diagnostic Observation Schedule or the Autism Diagnostic Interview-Revised.
  • Participants must receive ABA therapy at Cortica, with scheduled ABA sessions in clinic at least 3 times per week.
  • Participants must be able to tolerate VR therapy in the judgement of parent or caregiver and study staff

You may not qualify if:

  • A history of photosensitive epilepsy, or photoparoxysmal response on electroencephalogram (EEG)
  • Active diagnosis of migraine headache or migraine variant (abdominal migraine, cyclic vomiting syndrome), not adequately controlled
  • History of balance disorder including vertigo, motion sensitivity, or balance disorder
  • Primary sensory impairment (blindness, deafness)
  • Motor disorder that would interfere with VR engagement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cortica

Thousand Oaks, California, 91361, United States

Location

Related Publications (1)

  • Kanne SM, Mazurek MO, Sikora D, Bellando J, Branum-Martin L, Handen B, Katz T, Freedman B, Powell MP, Warren Z. The Autism Impact Measure (AIM): initial development of a new tool for treatment outcome measurement. J Autism Dev Disord. 2014 Jan;44(1):168-79. doi: 10.1007/s10803-013-1862-3.

    PMID: 23748386BACKGROUND

Related Links

MeSH Terms

Conditions

Autism Spectrum DisorderCommunication

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental DisordersBehavior

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Subjects and their parents/caregivers will be blinded to whether they are receiving Floreo VR therapy vs active VR exposure control. Research staff administering the therapy or control will not be blinded to the therapy; however, the clinicians doing pre/post assessments will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The two parallel groups include an experimental group that will receive the Floreo VR Building Social Connections program and a control group that will receive non-interventional active VR programing.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2023

First Posted

March 30, 2023

Study Start

February 15, 2023

Primary Completion

June 29, 2023

Study Completion

June 29, 2023

Last Updated

February 26, 2025

Record last verified: 2025-02

Locations